Literature DB >> 22599359

Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia.

Chin Kook Rhee1, Kyung Hoon Min, Nam Yeol Yim, Ji Eun Lee, Na Rae Lee, Man Pyo Chung, Kyeongman Jeon.   

Abstract

The clinical characteristics and optimal duration of corticosteroid treatment for acute eosinophilic pneumonia (AEP) have not been fully evaluated. This was a retrospective study of prospectively collected data from 137 patients with AEP, treated with standardised protocol, to clarify the clinical characteristics and compare the efficacies of 2 weeks versus 4 weeks of corticosteroid treatment for AEP. The majority of the patients altered their smoking habits within a median (interquartile range) of 17 (13-26) days prior to development of AEP. 80 (58%) patients presented with acute respiratory failure. A total of 127 (92%) patients were treated with corticosteroids: 4 weeks, n=42; 2 weeks, n=85. Major symptoms were resolved in 3 days and the severity of respiratory failure was inversely correlated with clinical outcomes. After adjusting for differences in baseline characteristics between the groups, the differences in adjusted mean (95% confidence interval) for resolution of dyspnoea and disappearance of all symptoms were 0.57 (-0.71-1.86) and -0.04 (-1.91-1.83) days, respectively. The difference in adjusted proportion of resolution of radiological abnormalities was 6.92% (-8.19-22.02). In conclusion, the duration of corticosteroid treatment could be shortened to 2 weeks, even in patients with respiratory failure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22599359     DOI: 10.1183/09031936.00221811

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  37 in total

1.  Primary Cytomegalovirus-Related Eosinophilic Pneumonia in a Three-year-old Child with Acute Lymphoblastic Leukaemia: Case report and literature review.

Authors:  Mohammed Al Reesi; Amal Al-Maani; George Paul; Sumaiah Al-Arimi
Journal:  Sultan Qaboos Univ Med J       Date:  2014-10-14

2.  Pediatric Acute Respiratory Distress Syndrome and Hypersensitivity Pneumonitis Related to E-cigarette Vaping.

Authors:  Binh Phung; Anh Lam
Journal:  J Pediatr Intensive Care       Date:  2019-11-28

3.  Clinical outcomes in patients with acute eosinophilic pneumonia not treated with corticosteroids.

Authors:  Byung Woo Jhun; Se Jin Kim; Rak Chae Son; Hongseok Yoo; Byeong-Ho Jeong; Man Pyo Chung; Kyeongman Jeon
Journal:  Lung       Date:  2015-03-28       Impact factor: 2.584

Review 4.  Synergy of Interleukin (IL)-5 and IL-18 in eosinophil mediated pathogenesis of allergic diseases.

Authors:  Hemanth Kumar Kandikattu; Sathisha Upparahalli Venkateshaiah; Anil Mishra
Journal:  Cytokine Growth Factor Rev       Date:  2019-05-10       Impact factor: 7.638

5.  Vaping Associated Lung Injury (EVALI): An Explosive United States Epidemic.

Authors:  Gary A Salzman; Mohammed Alqawasma; Hussein Asad
Journal:  Mo Med       Date:  2019 Nov-Dec

Review 6.  Smoking-related interstitial lung disease.

Authors:  Lars Hagmeyer; Winfried Randerath
Journal:  Dtsch Arztebl Int       Date:  2015-01-23       Impact factor: 5.594

7.  Idiopathic Chronic Eosinophilic Pneumonia Evolving to Pulmonary Fibrosis: A Retrospective Analysis.

Authors:  Misbah Baqir; Tobias Peikert; Tucker F Johnson; Yasmeen K Tandon; Eunhee S Yi; Darrell R Schroeder; Jay H Ryu
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2022-06-29       Impact factor: 1.803

8.  Acute Eosinophilic Pneumonia Complicated with Venous Thromboembolic Disease-Diagnostic and Therapeutic Considerations.

Authors:  Ewa Jankowska; Iwona Bartoszuk; Katarzyna Lewandowska; Małgorzata Dybowska; Lucyna Opoka; Witold Tomkowski; Monika Szturmowicz
Journal:  Diagnostics (Basel)       Date:  2022-06-09

9.  Acute eosinophilic pneumonia.

Authors:  Jang Won Sohn
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-02-28

10.  Minocycline-induced acute eosinophilic pneumonia: A case report and review of the literature.

Authors:  Sharon W Hung
Journal:  Respir Med Case Rep       Date:  2015-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.